Clearmind Medicine CMND 深 滬
已收盤 07-02 16:00:00 美东时间
2.36
+0.060
+2.61%
華盛通- 最 高2.418
- 今 開2.28
- 成交量 6.65万股
- 最 低 2.28
- 昨 收 2.30
- 總市值 350.59万
- 52周最高 524.00
- 市盈率 靜 --
- 換手率 4.48%
- 52周最低 2.04
- 委 比 78.86%
- 總股本 148.56万
- 歷史最高 73200.00
- 量 比 0.06
- 振 幅 6.00%
- 歷史最低 2.20
- 每 手 1
- 風險率 183.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clearmind Medicine Granted Additional US Patent Titled BINGE BEHAVIOR REGULATORS By USPTO
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it h...
06-29 19:56
Clearmind Medicine Awarded U.S. Patent for Binge Behavior Regulators
The patent, which refers to Clearmind's molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, including excessive drinking, eating, and gambling. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, c...
06-18 19:56
Clearmind Medicine Completes Dosing Of All 24 Participants In Groups 1 To 4 Of Part A Of Its Phase I/II Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the succe...
06-16 19:36
Why Taylor Morrison Home Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announced to acquire the homebuilder.
06-01 18:01
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers PRF Technologies (NASDAQ:PRFX) stock rose 231.0% to $4.54 during Frida...
05-30 01:06
Clearmind Medicine Announces Johns Hopkins Approval For CMND-100 Phase 1/2 Clinical Trial
The approval advances the multicenter study titled "A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A,
05-26 20:35
BRIEF-Clearmind Medicine Announces 1-For-10 Reverse Share Split
BRIEF-Clearmind Medicine Announces 1-For-10 Reverse Share Split May 19 (Reuters) - Clearmind Medicine Inc CMND.O : CLEARMIND MEDICINE ANNOUNCES 1-FOR-10 REVERSE SHARE SPLIT CLEARMIND MEDICINE INC - REVERSE SHARE SPLIT EFFECTIVE MAY 21, 2026 TO REGAIN NASDAQ COMPLIANCE Source text: ID:nGNXb6GP6l Furt
05-19 18:00
Clearmind Medicine Announces 1-for-10 Reverse Share Split
Clearmind Medicine Inc. announced a 1-for-10 reverse share split to regain compliance with the Nasdaq Minimum Bid Price Rule, effective May 21, 2026. The board approved the plan on March 18, 2026. The split will reduce outstanding shares from 10,190,337 to ~1,019,033, with fractional shares rounded up. All options and warrants will be proportionally adjusted.
05-19 10:00
Clearmind Medicine Inks Research Agreement With Yissum Research Development To Evaluate Metabolic Efficacy Of MEAI Both In Combination With, Maintenance Therapy Following Tirzepatide Treatment In Diet-Induced Obese Mice
Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived
05-18 20:44
Clearmind Medicine Files European Patent Application For Innovative Psychedelic Compounds Targeting The Treatment Of Post-Traumatic Stress Disorder And Other Mental Health Disorders
The European patent application forms part of the Company's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"). Under the terms of the
05-05 20:52
